All
Search
Images
Videos
Shorts
Maps
News
More
Shopping
Flights
Travel
Notebook
Report an inappropriate content
Please select one of the options below.
Not Relevant
Offensive
Adult
Child Sexual Abuse
Length
All
Short (less than 5 minutes)
Medium (5-20 minutes)
Long (more than 20 minutes)
Date
All
Past 24 hours
Past week
Past month
Past year
Resolution
All
Lower than 360p
360p or higher
480p or higher
720p or higher
1080p or higher
Source
All
Dailymotion
Vimeo
Metacafe
Hulu
VEVO
Myspace
MTV
CBS
Fox
CNN
MSN
Price
All
Free
Paid
Clear filters
SafeSearch:
Moderate
Strict
Moderate (default)
Off
Filter
Treatment Approaches for TP53-Mutated AML | OncLive
Sep 9, 2021
onclive.com
Challenges in the Management of TP53-Mutated AML: Potential Strat
…
481 views
Mar 5, 2024
vumedi.com
Current and Future Options in TP53-Mutated AML
66 views
6 months ago
vumedi.com
Frontline Treatment in Patients With IDH-Mutated AML Unfit for Intensi
…
Feb 28, 2023
onclive.com
Activity, Tolerability and Resistance Profile of the Menin Inhibitor Zifto
…
1 week ago
onclive.com
Unmet Needs for Patients With AML | Targeted Oncology - Immunother
…
Jan 3, 2024
targetedonc.com
13:50
Phase 1b Study of Azacitidine, Venetoclax and Revumenib in Ne
…
Jul 23, 2024
onclive.com
Dr Fedorov on the Use of Quizartinib vs Midostaurin in FLT3 AML | Onc
…
Apr 26, 2024
onclive.com
Treatment Options for AML Patients with IDH2, RUNX1, or DNMT3A Mu
…
Aug 8, 2022
targetedonc.com
8:26
Bispecific Antibodies and CAR T-Cell Therapy: Emerging Data in TP
…
501 views
1 month ago
YouTube
OncUpdates: Latest Oncology Insights
1:52
Treating patients with FLT3-mutated AML: What you need to know
156 views
3 weeks ago
YouTube
Know AML
2:05
Onyee Chan, MD: VEN/HMA vs IDHi as frontline options in IDH-mutate
…
9 views
2 months ago
YouTube
Moffitt Cancer Center
2:14
Real-world outcomes of olutasidenib in IDH1-mutated AM
…
2 views
1 month ago
YouTube
VJHemOnc – Video Journal of Hematology & H…
2:09
ASHOP: Figure 3D
1 views
3 months ago
YouTube
Congyu Lu
9:27
This New Drug is a Game Changer for Leukemia
10 views
2 months ago
YouTube
RxIndianPharmacist
1:31
A Phase II trial investigating crenolanib plus salvage chemothe
…
18 views
2 months ago
YouTube
VJHemOnc – Video Journal of Hematology & H…
1:46
Outcomes and patterns of relapse of NPM1-mutated AML treated with v
…
8 views
1 month ago
YouTube
VJHemOnc – Video Journal of Hematology & H…
4:13
HMAs or chemotherapy with venetoclax and gilteritinib for FLT
…
12 views
2 weeks ago
YouTube
VJHemOnc – Video Journal of Hematology & H…
4:03
Choice of HMA for newly diagnosed TP53-mutant AML: a COMMAND r
…
19 views
2 weeks ago
YouTube
VJHemOnc – Video Journal of Hematology & H…
2:31
Azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT
…
23 views
3 weeks ago
YouTube
VJHemOnc – Video Journal of Hematology & H…
3:31
VICEROY study: azacitidine, venetoclax, and gilteritinib in FLT
…
30 views
2 weeks ago
YouTube
VJHemOnc – Video Journal of Hematology & H…
3:58
Clinical research round-up: Current and emerging treatments for IDH1
…
114 views
3 months ago
YouTube
AML Hub
1:15
MRD as a surrogate endpoint in NPM1-mutated AML: implications
…
2 views
2 weeks ago
YouTube
VJHemOnc – Video Journal of Hematology & H…
7:35
Azacitidine Plus Venetoclax vs 7 + 3 in AML: Practice-Changing Insight
…
531 views
1 month ago
YouTube
OncUpdates: Latest Oncology Insights
1:11
FRIDA study: iadademstat and gilteritinib in FLT3-mutated R/R AML
1 views
2 weeks ago
YouTube
VJHemOnc – Video Journal of Hematology & H…
0:35
Shelley loved her long walks—until she started feeling unusually tire
…
193 views
2 months ago
TikTok
patientstory
6:35
Understanding AML
173.6K views
Dec 2, 2019
YouTube
You and AML
2:26
What Is FLT3-Mutated Acute Myeloid Leukemia?
833 views
Feb 8, 2023
YouTube
Patient Empowerment Network
Azacitidine, venetoclax & gilteritinib in older/unfit patients with FLT3-m
…
728 views
Jun 20, 2023
YouTube
VJHemOnc – Video Journal of Hematology & H…
Which AML patients benefit most from venetoclax treatment?
3.6K views
Feb 17, 2022
YouTube
AML Hub
See more videos
More like this
Feedback